Collaboration and License Agreements - Lilly (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Feb. 28, 2022
Collaborative Agreements disclosures
Aggregate amount of transaction price allocated to remaining performance obligations	$ 63,900		$ 63,900
Revenue from contract with customer	113,425	$ 15,375	246,447	$ 67,615
Amount of obligation included in long-term deferred revenue	26,718		26,718		$ 36,355
Lilly
Collaborative Agreements disclosures
License agreement upfront payment receivable						$ 13,000
License agreement additional payment receivable						19,500
License agreement, target selection fees and development, regulatory and commercial milestone payments receivable						$ 1,700,000
Lilly | Upfront payment
Collaborative Agreements disclosures
License agreement upfront payment receivable		$ 19,500		19,500
Lilly | Initial targets
Collaborative Agreements disclosures
Revenue from contract with customer				$ 13,800	18,400
Lilly | Additional targets
Collaborative Agreements disclosures
License agreement additional payment receivable					$ 13,000
Lilly | Material rights to obtain licenses to replacement targets
Collaborative Agreements disclosures
Amount of obligation included in long-term deferred revenue	$ 7,600		$ 7,600